HEAT investigational therapy (HER2 antibody therapy with Lutetium-177)

HER2-targeted antibody radiopharmaceutical with Lutetium-177 · Radiopharm Theranostics, Ltd

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HEAT investigational therapy (HER2 antibody therapy with Lutetium-177), covering 2026-02-11 to 2026-02-11. Get the full timeline:

Most recent: Clinical Trial Update: HEAT Trial (HER2 Antibody Therapy With Lutetium-177) [EARLY_Phase 1]

See pricing